Oxford BioMedicaOXBDF 71 Forward PE Ratio is 0.00 as of Jul. 06, 2026. GuruFocus rates OXBDF with a GF Score™ of 71/100 and a GF Value™ of $7.11 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 355 Biotechnology companies, Oxford BioMedica ranks worse than 281689.86% on this metric.
Oxford BioMedica (OTCPK:OXBDF) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Oxford BioMedica Forward PE Ratio Related Terms
Oxford BioMedica Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Oxford BioMedica's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford BioMedica Forward PE Ratio Chart
Oxford BioMedica Annual Data
Trend
2017-12
2018-12
2019-12
2020-12
2021-12
Forward PE Ratio
166.67
41.49
46.51
92.59
40.32
Oxford BioMedica Semi-Annual Data
2017-12
2018-06
2018-12
2019-06
2019-12
2020-06
2020-12
2021-06
2021-12
Forward PE Ratio
166.67
81.97
41.49
61.35
46.51
92.59
92.59
86.21
40.32
OXBDF vs VRTX, REGN, ALNY: Forward PE Ratio Comparison
For the Biotechnology subindustry, Oxford BioMedica's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioMedica Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxford BioMedica's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Oxford BioMedica's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Oxford BioMedica (OXBDF) has a Forward PE Ratio of 0.00 as of Jul. 06, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Oxford BioMedica and its competitors. According to the industry distribution chart, Oxford BioMedica ranks #999999 out of 355 companies in the Biotechnology industry.
Is Oxford BioMedica's Forward PE Ratio too high?
Oxford BioMedica's current Forward PE Ratio is 0.00. Based on the distribution chart, Oxford BioMedica ranks #999999 out of 355 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oxford BioMedica has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxford BioMedica ranks #999999 out of 355 companies for Forward PE Ratio. This places Oxford BioMedica in the lower half of its industry. The industry median Forward PE Ratio is 22.37. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.37, based on 355 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Oxford BioMedica and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxford BioMedica's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (OXBDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.11, compared to a current price of $7.93 — trading 11.5% above its estimated fair value. The current Forward PE Ratio is 0.00. Oxford BioMedica's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Oxford BioMedica (OXBDF), the current Forward PE Ratio is 0.00 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxford BioMedica (OXBDF) Overvalued in 2026?
Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued.
The current stock price of $7.93 is trading 11.5% above its estimated GF Value™ of $7.11.
GuruFocus considers Oxford BioMedica to be Modestly Overvalued.
Key valuation signals for OXBDF:
Forward PE Ratio: 0.00
GF Value™: $7.11 vs. price of $7.93 (11.5% above fair value)
No single metric tells the full story. See the OXBDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
71GF Score
Get the complete analysis for OXBDF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OXBDF has been successfully added to your 